相似文献
1
Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.
Vaccine. 2011 Apr 12;29(17):3276-83. doi: 10.1016/j.vaccine.2011.02.023. Epub 2011 Feb 23.
2
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
J Virol. 2008 Apr;82(7):3517-29. doi: 10.1128/JVI.01854-07. Epub 2008 Jan 16.
3
Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.
J Virol. 2007 Aug;81(16):8774-83. doi: 10.1128/JVI.00538-07. Epub 2007 Jun 6.
4
E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Viruses. 2018 Jan 4;10(1):21. doi: 10.3390/v10010021.
5
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Virology. 2005 Sep 1;339(2):164-75. doi: 10.1016/j.virol.2005.06.002.
6
Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.
Virus Res. 2013 Dec 26;178(2):374-82. doi: 10.1016/j.virusres.2013.09.016. Epub 2013 Sep 16.
7
The poxvirus A35 protein is an immunoregulator.
J Virol. 2010 Jan;84(1):418-25. doi: 10.1128/JVI.01802-09.
8
Clinical development of Modified Vaccinia virus Ankara vaccines.
Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21.
9
Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
J Virol. 2014 Mar;88(6):3392-410. doi: 10.1128/JVI.02723-13. Epub 2014 Jan 3.
10
Highly immunogenic variant of attenuated vaccinia virus.
Dokl Biochem Biophys. 2016;466:35-8. doi: 10.1134/S1607672916010105. Epub 2016 Mar 31.
引用本文的文献
1
Gene amplification acts as a molecular foothold to facilitate cross-species adaptation and evasion of multiple antiviral pathways.
Virus Evol. 2022 Nov 14;8(2):veac105. doi: 10.1093/ve/veac105. eCollection 2022.
2
Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months.
Vaccines (Basel). 2022 Sep 15;10(9):1532. doi: 10.3390/vaccines10091532.
3
Genome-Wide Analysis and Molecular Characterization of Orf Virus Strain UPM/HSN-20 Isolated From Goat in Malaysia.
Front Microbiol. 2022 Jul 11;13:877149. doi: 10.3389/fmicb.2022.877149. eCollection 2022.
4
Enhancing the Immunogenicity of Vaccinia Virus.
Viruses. 2022 Jun 30;14(7):1453. doi: 10.3390/v14071453.
5
Extracellular Vesicles and Their Use as Vehicles of Immunogens.
Methods Mol Biol. 2022;2504:177-198. doi: 10.1007/978-1-0716-2341-1_13.
6
Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.
Biomedicines. 2021 Nov 26;9(12):1780. doi: 10.3390/biomedicines9121780.
7
Enhancing the Protective Immune Response to Administration of a LIVP-GFP Live Attenuated Vaccinia Virus to Mice.
Pathogens. 2021 Mar 21;10(3):377. doi: 10.3390/pathogens10030377.
8
Genes that Control Vaccinia Virus Immunogenicity.
Acta Naturae. 2020 Jan-Mar;12(1):33-41. doi: 10.32607/actanaturae.10935.
9
Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.
Viruses. 2018 Feb 28;10(3):101. doi: 10.3390/v10030101.
10
Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.
PLoS One. 2018 Feb 23;13(2):e0193131. doi: 10.1371/journal.pone.0193131. eCollection 2018.
本文引用的文献
1
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16262-7. doi: 10.1073/pnas.1005769107. Epub 2010 Aug 30.
2
Vaccinia virus A35R inhibits MHC class II antigen presentation.
Virology. 2010 Feb 5;397(1):176-86. doi: 10.1016/j.virol.2009.11.008. Epub 2009 Dec 2.
3
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
Infect Immun. 2010 Jan;78(1):145-53. doi: 10.1128/IAI.00740-09. Epub 2009 Oct 26.
4
Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
Vaccine. 2009 Oct 23;27(45):6296-9. doi: 10.1016/j.vaccine.2009.03.020.
5
The poxvirus A35 protein is an immunoregulator.
J Virol. 2010 Jan;84(1):418-25. doi: 10.1128/JVI.01802-09.
6
Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.
Vaccine. 2009 Dec 10;28(1):38-47. doi: 10.1016/j.vaccine.2009.09.126. Epub 2009 Oct 12.
7
Cowpox virus outbreak in banded mongooses (Mungos mungo) and jaguarundis (Herpailurus yagouaroundi) with a time-delayed infection to humans.
PLoS One. 2009 Sep 3;4(9):e6883. doi: 10.1371/journal.pone.0006883.
8
Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14954-9. doi: 10.1073/pnas.0904021106. Epub 2009 Aug 17.
9
Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines.
Vaccine. 2009 Sep 25;27(42):5885-95. doi: 10.1016/j.vaccine.2009.07.039. Epub 2009 Aug 3.
10
Natural human infections with Vaccinia virus during bovine vaccinia outbreaks.
J Clin Virol. 2009 Apr;44(4):308-13. doi: 10.1016/j.jcv.2009.01.007. Epub 2009 Feb 24.
Zotero 插件